The FDA last week approved Samsung Bioepis's...

...Ontruzant, a biosimilar to Roche's Herceptin, a breast cancer treatment that is among the pharma company's top sellers. 12% of all covered lives currently have access to Herceptin on the preferred tier, while another 7% have preferred access after prior authorization/step therapy. The FDA has approved two other Herceptin biosimilars in recent years, Celltrion and Teva's Herzuma, and Mylan's Ogivri, though neither of them have launched. Roche's U.S. patent for Herceptin is set to expire this June. 

SOURCE: MMIT Analytics, as of 1/25/19